Paper · 20728210

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Bang YJ and 16 others. Lancet, 2010. Cited by 5,921 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Papers, record 20728210. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20728210

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.; PubMed
Journal: Lancet; PubMed
Year: 2010; PubMed
Publication types: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/20728210/; PubMed
DOI: https://doi.org/10.1016/s0140-6736(10)61121-x; PubMed
The journal: https://conductscience.org/library/journal-index/2985213R; PubMed
Citations, by iCite: 5,921; iCite
Relative citation ratio, by iCite: 152; iCite
Revised in PubMed: 2026-05-18; PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Bang YJ	Yung-Jue
2	Van Cutsem E	Eric
3	Feyereislova A	Andrea
4	Chung HC	Hyun C
5	Shen L	Lin
6	Sawaki A	Akira
7	Lordick F	Florian
8	Ohtsu A	Atsushi
9	Omuro Y	Yasushi
10	Satoh T	Taroh

1 to 10 of 17Source PubMed

See all 17 authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Adenocarcinoma	Major topic
Antibodies, Monoclonal	Major topic
Antineoplastic Agents	Major topic
Esophagogastric Junction	Major topic
Stomach Neoplasms	Major topic
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Capecitabine
Cisplatin
Deoxycytidine
Drug Therapy, Combination
Female
Fluorouracil
Humans
Male
Middle Aged
Erb-b2 Receptor Tyrosine Kinases
Survival Analysis
Trastuzumab
Treatment Outcome

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials20

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT01041404	ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer	Derived from the trial	Yes	ClinicalTrials.gov
NCT01191697	CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer	Background		ClinicalTrials.gov
NCT01396707	Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX	Background		ClinicalTrials.gov
NCT02004769	Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer	Background		ClinicalTrials.gov
NCT02250209	T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy	Results		ClinicalTrials.gov
NCT02852096	Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks	Results		ClinicalTrials.gov
NCT03023436	Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis	Background		ClinicalTrials.gov
NCT03024450	Trastuzumab Based Therapy in HER2 Positive AGC	Results		ClinicalTrials.gov
NCT03229096	Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer	Background		ClinicalTrials.gov
NCT03978078	A Clinicobiological Database in Metastatic Digestive Cancers	Background		ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers	Source
Comment in	20,728,211	Cancer research in the global village.	https://conductscience.org/library/papers/20728211	PubMed
Comment in	21,049,571	Targeted therapies: New standard of therapy for HER2-positive gastric cancers?	https://conductscience.org/library/papers/21049571	PubMed
Comment in	21,087,674	Adding trastuzumab to standard chemotherapy in HER2-positive esophagogastric adenocarcinoma: a further step toward personalized medicine.	https://conductscience.org/library/papers/21087674	PubMed
Comment in	21,093,641	Trastuzumab for gastric cancer treatment.	https://conductscience.org/library/papers/21093641	PubMed
Comment in	21,174,864	Trastuzumab for HER2-positive gastric and gastroesophageal junction cancers.	https://conductscience.org/library/papers/21174864	PubMed

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by3,968

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5,921 citations.

PMID	Title	Journal	Year	In Papers	Source
42,968,171	Affinity-tuned anti-idiotypic masking enables protease-activatable HER2-targeting antibodies with an optimized masked-unmasked dynamic range.	J Biol Eng	2026	https://conductscience.org/library/papers/42968171	PubMed
42,964,552	Advanced Gastric Cancer With Cutaneous Metastases, With Effective Relief From Immunotherapy: Case Report.	Case Rep Surg	2026	https://conductscience.org/library/papers/42964552	PubMed
42,960,110	Artificial intelligence across the gastric cancer care continuum: Clinical evidence, multimodal integration, and translation.	iScience	2026	https://conductscience.org/library/papers/42960110	PubMed
42,959,918	Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy.	ESMO Gastrointest Oncol	2026	https://conductscience.org/library/papers/42959918	PubMed
42,959,646	Gastric Cancer: Epidemiology, Risk Factors, Pathogenesis, Clinical Features, Diagnosis, and Management.	MedComm (2020)	2026	https://conductscience.org/library/papers/42959646	PubMed
42,959,345	Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states.	Front Med (Lausanne)	2026	https://conductscience.org/library/papers/42959345	PubMed
42,958,443	HER2 in solid tumors: microenvironment features and multifaceted advances from mechanisms to clinical translation.	Exp Hematol Oncol	2026	https://conductscience.org/library/papers/42958443	PubMed
42,948,686	Improvement of survival in advanced gastric cancer over 15 years: real-world analysis by 5-year periods.	ESMO Gastrointest Oncol	2026	https://conductscience.org/library/papers/42948686	PubMed
42,948,023	Metastasis Pattern-Specific Biomarkers and Therapeutic Targets in Gastric Cancer: From Surgical Specimens to Clinical Translation.	Ann Gastroenterol Surg	2026	https://conductscience.org/library/papers/42948023	PubMed
42,941,329	Molecular Profiles, Treatment-Associated Survival, and Prognosis in Early-Onset Versus Late-Onset Gastric Cancer: A Systematic Review and Meta-Analysis.	J Clin Med	2026	https://conductscience.org/library/papers/42941329	PubMed

1 to 10 of 3,968

See all 3,968 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064

Source NCBI Gene

Drugs7

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
CISPLATIN	CHEMBL11359	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL11359	ChEMBL
BEVACIZUMAB	CHEMBL1201583	Results	1	https://conductscience.org/library/drugs/CHEMBL1201583	ChEMBL
TRASTUZUMAB	CHEMBL1201585	Results	3	https://conductscience.org/library/drugs/CHEMBL1201585	ChEMBL
CAPECITABINE	CHEMBL1773	Results	4	https://conductscience.org/library/drugs/CHEMBL1773	ChEMBL
FLUOROURACIL	CHEMBL185	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL185	ChEMBL
OXALIPLATIN	CHEMBL414804	Results	3	https://conductscience.org/library/drugs/CHEMBL414804	ChEMBL
SINTILIMAB	CHEMBL4297829	Results	1	https://conductscience.org/library/drugs/CHEMBL4297829	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20728210

GET https://conductscience.org/api/papers/v1/20728210/cited_by?page=2

API reference For AI assistants